Cuba has anti-Covid-19 schemes that exceed the limit imposed by the World Health Organization. Photo: Prensa Latina
–
A load of 900 thousand doses of the Abdala vaccine from Cuba arrived in Venezuela, where it will contribute to immunize the people of that South American nation against Covid-19.
‘New shipment from Abdala reaches sister Venezuela. This morning, 900 thousand doses of our Cuban vaccine arrived in Caracas, to help the beloved Venezuelan people in the fight against the current pandemic due to Covid-19 ‘, highlights a message from the Center for Genetic Engineering and Biotechnology (CIGB) in his account from the social network Twitter.
It was also known that the day before, the Health Regulation Authority of the Ministry of Health of Nicaragua granted the Emergency Use Certification to the Cuba Soberana 02 and Abdala vaccines.
‘The Health Regulation Authority of the Nicaraguan Ministry of Health (MINSA) grants the Emergency Use Certification to the Cuban vaccines #Soberana and #Abdala’ underlines a message from the company BioCubaFarma on the social network of Twitter.
‘This certification granted by the Nicaraguan Regulatory Authority indicates that the Soberana 02 and Abdala vaccines are offered as a therapeutic tool with safe access to reduce the transmissibility of Covid-19, produced by the SARS-Cov-2 virus,’ he points out. the Antillean entity.
Cuba has anti-Covid-19 schemes that exceed the limit imposed by the World Health Organization (50 percent) to be declared vaccines and in that sense, Abdala, has already received authorization for emergency use in the country, as has Soberana 02 for the pediatric population.
Abdala, designed by the Center for Genetic Engineering and Biotechnology (CIGB), the first vaccine in Latin America, showed 92.28 percent efficacy in its three-injection scheme.
Likewise, the Finlay Institute of Vaccines (IFV) Sovereign 02 vaccine is added, which, with two injections, showed in its final analysis of the efficacy on the symptomatic disease a 65.6 percent, data that increased after 62 percent reported in the intermediate study.
The IFV also announced the efficacy of 91.2 percent of the two-dose schedule of Soberana 02 plus one of the Soberana Plus vaccine.
To the Cuban immunogens mentioned above are added the candidates Mambisa, also from the CIGB and the only one to be applied nasal, which obtained permission from the local health authorities to start phase II of clinical trials; and Soberana 01, from the IFV.
(With information from Prensa Latina)
– .
